Sugi Predict

Sugi Predict / Compounds / SCHEMBL215719

SCHEMBL215719

SCHEMBL215719

CC(C)(C)OC(=O)NCc1nc(Br)cs1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC3 O15379 3/20 0.51
▸ HDAC1 Q13547 3/20 0.51
▸ HDAC6 Q9UBN7 3/20 0.51
▸ KDM4A O75164 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ PDPK1 O15530 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ CACNA1H O95180 1/20 0.39
▸ CACNA1B Q00975 1/20 0.39
▸ CACNA1C Q13936 1/20 0.39
▸ CA12 O43570 2/20 0.38
▸ CA1 P00915 2/20 0.38
▸ CA2 P00918 2/20 0.38
▸ CA9 Q16790 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ROCK2 O75116 1/20 0.38
▸ GLS O94925 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16020352 0.85 HDAC3 (0.48) HDAC3HDAC1HDAC6KDM4AKDM4E
SCHEMBL8053542 0.85 HDAC3 (0.46) HDAC3HDAC1HDAC6KDM4AKDM4E
SCHEMBL4573058 0.84 HDAC3 (0.47) HDAC3HDAC1HDAC6KDM4AKDM4E
SCHEMBL1852466 0.83 HDAC3 (0.52) HDAC3HDAC1HDAC6KDM4AKDM4E
SCHEMBL18136859 0.83 HDAC3 (0.47) HDAC3HDAC1HDAC6KDM4AKDM4E
SCHEMBL31147895 0.83 HDAC3 (0.49) HDAC3HDAC1HDAC6KDM4AKDM4E
SCHEMBL19370070 0.83 HDAC3 (0.52) HDAC3HDAC1HDAC6KDM4AKDM4E
SCHEMBL17295921 0.83 HDAC3 (0.52) HDAC3HDAC1HDAC6KDM4AKDM4E
SCHEMBL22046576 0.83 HDAC3 (0.47) HDAC3HDAC1HDAC6KDM4AKDM4E
SCHEMBL8041524 0.83 HDAC3 (0.47) HDAC3HDAC1HDAC6KDM4AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199651-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2024-06-20 — — US disclosed
CN-117580843-A Antibacterial compounds 爱尔兰詹森科学公司 2024-02-20 — — CN disclosed
CN-117440958-A Antibacterial compounds 爱尔兰詹森科学公司 2024-01-23 — — CN disclosed
US-11608330-B2 Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2023-03-21 — — US disclosed
US-20220372028-A1 Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2022-11-24 — — US disclosed
WO-2022194906-A1 ANTIBACTERIAL COMPOUNDS Janssen Sciences Ireland Unlimited Company (IE) 2022-09-22 — — WO disclosed
CN-109311839-B Methylamine derivatives as lysyl oxidase inhibitors for the treatment of cancer 癌症研究协会皇家癌症医院 2021-11-02 — — CN disclosed
WO-2020064175-A1 INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION ANTABIO SAS (FR) 2020-04-02 — — WO disclosed
EP-3628672-A1 INDANE DERIVATIVES FOR USE IN THE TREATMENT OF BACTERIAL INFECTION Antabio SAS (FR) 2020-04-01 — — EP disclosed
CN-109311839-A Methylamine derivative is used for treating cancer as lysyl oxidase inhibitor 癌症研究协会皇家癌症医院 2019-02-05 — — CN disclosed
WO-2017141049-A1 METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) 2017-08-24 — — WO disclosed
US-8088766-B2 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA INC. (US) 2012-01-03 — — US disclosed
US-7488823-B2 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA, INC. (US) 2009-02-10 — — US disclosed
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA, INC. (US) 2009-01-08 — — US disclosed
EP-1567506-A4 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA INC (US) 2007-06-20 — — EP disclosed
EP-1567506-A2 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS Array Biopharma, Inc. (US) 2005-08-31 — — EP disclosed
US-20050101617-A1 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ARRAY BIOPHARMA, INC. 2005-05-12 — — US disclosed
WO-2004046101-A2 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ARRAY BIOPHARMA, INC. (US) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199651-A1 ANTIBACTERIAL COMPOUNDS FDPS, MT-ND4, NDUFS3 HDAC3 865/4885HDAC1 1174/4885HDAC6 591/4885
US-20090012290-A1 CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS ERBB2, GRB2, EGFR HDAC3 3964/4885HDAC1 3901/4885HDAC6 3777/4885
US-20220372028-A1 Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer LOXL1, LOXL3, LOXL2 HDAC3 3314/4885HDAC1 1718/4885HDAC6 3127/4885
US-20050101617-A1 Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors ERBB2, GRB2, EGFR HDAC3 3964/4885HDAC1 3901/4885HDAC6 3777/4885
US-11608330-B2 Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer LOXL1, LOXL3, LOXL2 HDAC3 3314/4885HDAC1 1718/4885HDAC6 3127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.